NCT00691028 - Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis | Biotech Hunter

Enrollment

327

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions

Rheumatoid Arthritis

Interventions

DRUG

TA-650 3 mg/kg

3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.

DRUG

TA-650 6 mg/kg

3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.

DRUG

TA-650 10 mg/kg

3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.